David Allen, DO
Cardiovascular Disease · Bethlehem, PANPI 1669693834
Payments from drug & device makers
Across 476 payments — averaging $740.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$96K
- Boehringer Ingelheim$92K
- Actelion Pharmaceuticals US, Inc.$78K
- Bayer$29K
- Lilly USA, LLC$20K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11K
- plus $28K from 15 others
What the payments were for
- Consulting fees$22,6376%
- Speaking & faculty fees$300,82385%
- Travel & lodging$13,7544%
- Food & beverage$15,0344%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 114 | $95,960 |
| Boehringer Ingelheim | 96 | $91,603 |
| Actelion Pharmaceuticals US, Inc. | 100 | $77,543 |
| Bayer | 32 | $28,591 |
| Lilly USA, LLC | 25 | $20,126 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $10,629 |
| Impulse Dynamics (USA) Inc. | 18 | $8,961 |
| Novartis | 9 | $8,251 |
| Abbott | 23 | $5,713 |
| Bridgebio Pharma, Inc. | 3 | $2,366 |
| Edwards Lifesciences | 20 | $1,521 |
| Abiomed | 6 | $281 |
| Alnylam Pharmaceuticals Inc. | 2 | $241 |
| Vifor Pharma, Inc. | 1 | $200 |
| Boston Scientific | 2 | $177 |
| Merck | 2 | $44 |
| Kestra Medical Technology Services, Inc. | 1 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| AstraZeneca | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $12 |
| Akcea Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$107,680
- OPSUMIT$72,117
- UPTRAVI$72,072
- TYVASO$35,072
- ORENITRAM$25,604
- Adempas$15,057
- Kerendia$13,028
- OPTIMIZER$10,220
- LifeVest$10,181
- ENTRESTO$8,200
- REMODULIN$7,125
- CARDIOMEMS$4,988
- Attruby$2,366
- OPTIMIZER SMART SYSTEM$1,200
- SAPIEN 3 Ultra RESILIA$463
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$277
- Edwards SAPIEN 3 Transcatheter Heart Valve$221
- Veltassa$200
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$186
- VIGILANT$125
How this compares
$352,306 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 129 | $3,043,955 |
| AdempasRiociguat | 207 | $2,824,550 |
| VyndamaxTafamidis | 74 | $1,962,171 |
| OpsumitMacitentan | 115 | $1,440,455 |
| Orenitram ErTreprostinil Diolamine | 80 | $1,225,666 |
| UptraviSelexipag | 12 | $450,206 |
| EntrestoSacubitril/Valsartan | 433 | $412,789 |
| EliquisApixaban | 349 | $324,501 |
| WinrevairSotatercept-Csrk | 18 | $265,060 |
| JardianceEmpagliflozin | 261 | $200,393 |
| Ambrisentan | 35 | $111,741 |
| XareltoRivaroxaban | 74 | $97,894 |
| Tadalafil | 97 | $50,556 |
| Sildenafil Citrate | 160 | $35,355 |
| FarxigaDapagliflozin Propanediol | 38 | $28,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $28,591 | $2,824,550207 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $77,543 | $1,890,661127 claims |
| NovartisEntresto | $8,251 | $412,789433 claims |
| MerckWinrevair | $44 | $265,06018 claims |
| Boehringer IngelheimJardiance | $91,603 | $200,393261 claims |
| AstraZenecaFarxiga | $14 | $28,08338 claims |
| United Therapeutics CorporationAdcirca | $95,960 | $25,48112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Bethlehem
- Darren TraubBethlehem$381K
- Jamshid ShiraniBethlehem$242K
- Danielle DuffyPhiladelphia$29.5M
- Venkatesh NadarCamp Hill$18.3M
- Hemal GadaWormleysburg$6.7M
- Brian DrachmanPhiladelphia$3.8M
- William BachinskyMechanicsburg$2.3M
- Bonnie KyPhiladelphia$1.9M
- Benjamin KalsmithPgh$1.7M
- Marielle Scherrer CrosbiePhiladelphia$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.